Literature DB >> 2977647

Inhibition of intestinal pyrimidine nucleoside phosphorylases.

M G Wientjes1, J L Au.   

Abstract

The activity of 5'-deoxy-5-fluorouridine (dFUR) depends on its activation to 5-fluorouracil (FU) by pyrimidine nucleoside phosphorylases. These enzymes are found in tumors and normal tissues, with the highest activity in the small intestines. The present study examined the inhibition of dFUR phosphorolysis in intestinal tissues. dFUR metabolism in intestinal homogenates was inhibited by uracil (U), uridine (UR), and thymidine (TdR), which are the normal substrates for the phosphorylases. Conversely dFUR reduced the metabolism of these inhibitors. A good agreement was found between the observed data and the computer-fitted data using the equations for competitive inhibition between dFUR and the inhibitors. In the absence of inhibitors, the Vmax of dFUR phosphorolysis was 47.1 +/- 4.9 microM/min and the apparent Km was 910 +/- 167 microM. The Vmax was unaltered by the inhibitors, while the Km was increased with increasing inhibitor concentrations. The maximal inhibition of dFUR metabolism by UR and TdR was about 80%. The Ki's were 372 microM for U, 87.2 microM for UR, and 112 microM for TdR and are orders of magnitude higher than their reported endogenous serum concentrations. The rate of dFUR phosphorolysis to FU in the intact intestinal epithelial crypt cells, indicated by the ratio of FU to dFUR in the intracellular fluid, was reduced by UR in a concentration-dependent fashion. These data indicate that the naturally occurring pyrimidines inhibit competitively the dFUR metabolism by the intestinal phosphorylases, that this inhibition occurs at concentrations much higher than the circulating endogenous levels, and that phosphorolysis is the major route of dFUR metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2977647     DOI: 10.1023/a:1016446715114

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

1.  Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

2.  Quantitative high-performance liquid chromatography of nucleosides and bases in human plasma.

Authors:  G A Taylor; P J Dady; K R Harrap
Journal:  J Chromatogr       Date:  1980-10-10

3.  Thymidine and thymine in biologic fluids during high-dose infusions of thymidine in mice, monkeys, and man.

Authors:  D S Zaharko; B J Bolten; T Kobayashi; R G Blasberg; S S Lee; B C Giovanella; J S Stehlin
Journal:  Cancer Treat Rep       Date:  1979-06

4.  Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.

Authors:  M Tuchman; M L Ramnaraine; R F O'Dea
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

5.  Novel single-pass exchange of circulating uridine in rat liver.

Authors:  T Gasser; J D Moyer; R E Handschumacher
Journal:  Science       Date:  1981-08-14       Impact factor: 47.728

6.  Differential selectivity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia.

Authors:  J L Au; Y M Rustum; J Minowada; B I Srivastava
Journal:  Biochem Pharmacol       Date:  1983-02-01       Impact factor: 5.858

7.  Role of administration route in the therapeutic efficacy of doxifluridine.

Authors:  F Trave; L Canobbio; J L Au; Y M Rustum
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

8.  Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Tokyo Liver Cancer Chemotherapy Study Group.

Authors: 
Journal:  Jpn J Clin Oncol       Date:  1985-09       Impact factor: 3.019

9.  Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.

Authors:  R Abele; P Alberto; R J Seematter; G Germano; R Heintz; W Bollag
Journal:  Cancer Treat Rep       Date:  1982-06

10.  Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.

Authors:  A Leyva; C J van Groeningen; I Kraal; H Gall; G J Peters; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more
  2 in total

1.  Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.

Authors:  J L Au; M G Wientjes; S L Bramer
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.

Authors:  Y Sawai; K Yamaoka; T Nakagawa
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.